We’re in the midst of earnings season, and a couple of San Diego’s publicly traded biotechs recently updated investors this week with sales data and other financial insights. Here’s a look at those companies.

—Acadia Pharmaceuticals faced a setback in July with the failure of a late-stage trial that was testing pimavanserin—which the company’s sells under the name Nuplazid as a treatment for Parkinson’s disease-related psychosis—in people with schizophrenia who haven’t responded to other medications.

Investors, however, buoyed the company’s share price this week after Acadia (NASDAQ: ACAD) announced it anticipated that sales of Nuplazid, its sole commercial drug,… Read more »